Melbourne, Australia,: Agenix Limited (ASX: AGX) is pleased to announce that it has entered into a co-operation and cross-licensing agreement with Scotland based Arrayjet Limited, a specialist with existing expertise and intellectual property in microarray technology.

The agreement commits the partners to undertake R & D both in Scotland and Australia to jointly develop a Point of Care test (POCT) that seeks to combine the speed, portability and ease of use of Agenix’s patented flow through DiagnostIQ® POCT platform with the sensitivity, accuracy and multiplexing ability of planar microarray technology.

Arrayjet’s patented, non-contact, inkjet printing technology is used to manufacture precision, high quality, reproducible microarrays. The parties aim to meet the costs of development in part by research grants and access to R & D tax incentives.

Agenix Chairman and Chief Executive, Nick Weston said: “Partnering with Arrayjet is an important step in the development of our DiagnostiQ® licenced technology for human health applications. There is a high unmet medical need for a platform able to do multiplexed affinitybased assays in low-resource or mobile settings.”

Arrayjet Chief Executive Officer, Dr. Iain McWilliam said: “Considering the rapid growth in the field of diagnostic biomarker panels, there are remarkably few multiplex tests on the market and even fewer content-ready, open platforms available to developers. We see the vertical flow, disposable cartridge at the heart of the DiagnostIQ® platform as the ideal vehicle for a multiplex diagnostic array. Our eventual aim will be to offer customers an end-to-end process, whereby they can rapidly translate a novel biomarker profile into a diagnostic tool presented on a reformatted version of DiagnostIQ® to afford the end-user a simple-to-use, cost effective solution.”

About Agenix

Agenix listed on the Australian Securities Exchange in 1987. Today, Agenix’s lead product candidate is ThromboView®, a novel radio-labelled monoclonal antibody imaging modality for pulmonary embolism (PE) and deep vein thrombosis (DVT). ThromboView® has successfully completed two U. S. FDA Phase II clinical trials and is in partnering discussions for Phase III trials.

Agenix’s human health diagnostics platform, DiagnostIQ® is a patented disposable point-ofcare test device with reader. DiagnostIQ® utilises an antibody/antigen printed membrane, a unique pre-filter device and an incubation chamber in a flow-through format to create a sensitive and quantitative, rapid, test. The patented technology provides the potential for

point-of-need testing that is simple and quick to use, gives rapid and accurate results. Agricultural rights for the platform are licensed to Bayer CropSciences AG.

Agenix has completed pre-clinical studies on AGX 1009, a next-generation reverse transcriptase inhibitor (NtRTI) prodrug of tenofovir. Agenix plans to divest this project and exit China operations following filing of the CFDA clinical trial application in 3Q 2013 to focus on its diagnostics business. Agenix owns all the patent rights to both ThromboView® and AGX

1009.

About Arrayjet

Arrayjet, headquartered in Roslin, Scotland, was founded in 2000 with the aim to develop a new, highly versatile non-contact microarray printing technology. With significant investment from Archangel Informal Investment group and the Scottish Government, Arrayjet developed a unique, inkjet microarray platform technology. This technology was launched in 2005, with the Marathon microarrayer, the first in a range of four instruments. The install base for Arrayjet’s microarrayers has continued to grow, with a worldwide user base and customers across 17 countries.

In 2011 Arrayjet Advance™ microarray services were launched providing customers with access to Arrayjet’s highly experienced scientific team and unique inkjet non-contact printing technology on a fee for service basis. Arrayjet Advance services include; routine array manufacturing, microarray assay development & optimisation, and custom array printing

projects.

Arrayjet’s platform technology delivers unrivalled speed, reproducibility and precision using unique, non-contact, inkjet printing for the manufacture of high quality microarrays of proteins, cell lysates, carbohydrates, lectins, nucleic acid, on a diverse range of substrates.